医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Toyoda Gosei Invests in Yuurea, Inc., a Startup Developing Urine Test Kits for Easy Checks of Physical Condition

2024年03月25日 PM03:00
このエントリーをはてなブックマークに追加


 

KIYOSU, Japan

Toyoda Gosei Co., Ltd. (TOKYO:7282), as one part of its efforts to develop new businesses that will help to resolve societal challenges in the healthcare field, has invested* in Yuurea, Inc., a company that develops test kits which will allow people to monitor their physical condition simply, using urine samples.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240324521742/en/

Test kit developed by Yuurea, Inc. (Photo: Business Wire)

Test kit developed by Yuurea, Inc. (Photo: Business Wire)

Yuurea aims to spread services that will lead to improved health habits by combining urine test kits with a smartphone app. Yuurea’s app is used to photograph urine test strips and instantly analyze nutritional status and more with the company’s original image processing technology. This provides useful data that will help people to maintain and improve their health.

Toyoda Gosei is committed to collaborating with other companies and developing products in the field of preventive medicine as a way to help society deal with the challenges brought on by increased longevity. The company will continue to cultivate business in the healthcare field by encouraging the spread of products and services related to preventive medicine, including among its own employees and those of its business partners.

* Investment made in March 2024, through Toyoda Gosei’s Corporate Venture Capital Dept., an internal organization dedicated to these investments.

Outline of Yuurea, Inc.

Name

Yuurea, Inc.

Location

Meieki Daiya Meitetsu Building 11F,

1-1-17 Meieki, Nishi-ku, Nagoya, Japan

President

Shogo Mizuno

Established

April 2021

Capital

JPY 34.1 million (as of March 6, 2024)

View source version on businesswire.com: https://www.businesswire.com/news/home/20240324521742/en/

CONTACT

Toyoda Gosei Co., Ltd.

Public Relations

inquiry@mlist.toyoda-gosei.co.jp

同じカテゴリーの記事 

  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表
  • The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report
  • Masimo创始人兼首席执行官Joe Kiani将在智利举行的全球患者安全峰会上谈论人工智能
  • マシモ創業者兼最高経営責任者(CEO)のジョー・キアニがチリで開催される世界患者安全サミットでAIについて講演
  • Codone Biotech to Present Data on its Suppressor-tRNA Platform in Disease Models with Nonsense Mutations (Premature Termination Codons)